Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 21 versus DASETTA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 21 versus DASETTA 1 35.
BALZIVA-21 vs DASETTA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-21 is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) signaling by binding to VEGF-A and preventing its interaction with VEGF receptors (VEGFR-1 and VEGFR-2), thereby reducing angiogenesis and tumor vascularization.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
BALZIVA-21 is administered 150 mg orally twice daily.
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
None Documented
None Documented
Terminal half-life: 18 hours (range 12-24 hr); prolonged in renal impairment
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Renal: 70% unchanged; biliary/fecal: 20%; 10% metabolized
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Category C
Category C
Oral Contraceptive
Oral Contraceptive